Sbi Securities Co., Ltd. Akebia Therapeutics, Inc. Transaction History
Sbi Securities Co., Ltd.
- $3.9 Trillion
- Q3 2025
A detailed history of Sbi Securities Co., Ltd. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Sbi Securities Co., Ltd. holds 4,553 shares of AKBA stock, worth $7,740. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,553
Previous 7,539
39.61%
Holding current value
$7,740
Previous $27.4 Million
54.7%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding AKBA
# of Institutions
189Shares Held
121MCall Options Held
267KPut Options Held
280K-
Vanguard Group Inc Valley Forge, PA15.5MShares$26.4 Million0.0% of portfolio
-
State Street Corp Boston, MA11.8MShares$20.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$19.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.18MShares$10.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$9.77 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $313M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...